News >

Choueiri Covers CABOSUN Excitement and Beyond in RCC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Sep 27, 2017

Toni K. Choueiri, MD

Toni K. Choueiri, MD
The potential practice-changing CABOSUN findings presented at the 2017 ESMO Congress validated the investigator-assessed results the oncology community learned of more than 1 year prior. With an independent review, frontline treatment with cabozantinib (Cabometyx) was found to demonstrate superiority in progression-free survival (PFS) over sunitinib in patients with advanced renal cell carcinoma (RCC).

In an interview with OncLive during the 2017 ESMO Congress, Toni K. Choueiri, MD, director of the Kidney Cancer Center at Dana-Farber Cancer Institute, shed light on the excitement surrounding the CABOSUN and CheckMate-214 trials, and why the future of the RCC field lies in novel combination regimens.

OncLive: Could you recap the main findings from the CABOSUN trial?

Choueiri: At the 2016 ESMO Congress, we presented CABOSUN results in the plenary session and we showed that, for the first time, a VEGF tyrosine kinase inhibitor (TKI) had antitumor activity, and it did provide superior PFS over sunitinib in metastatic RCC of intermediate and poor risk. The analysis was investigator-assessed, so what we did this time is provide an independent review with more follow-up for OS and [investigated] MET as a biomarker in the study.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x